product-product-categories-nuclear-imaging-agents-adreview-adreview-logo-pms.jpg

AdreView


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: AdreView is contraindicated in patients with known hypersensitivity to iobenguane or iobenguane sulfate.


See Indications and Important Safety Information about AdreView at the bottom of this page.

Please also read the Full Prescribing Information.

AdreView is the only FDA-approved I-123-meta-iodobenzylguanidine (I-123-mIBG) imaging agent indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma, as an adjunct to other diagnostic tests1

• Key benefits of AdreView include:

    – High sensitivity and specificity demonstrated in pivotal clinical trials in both newly diagnosed and previously treated neuroblastoma2 and pheochromocytoma3
    – As a GE Healthcare proprietary product, customers can count on outstanding product quality, consistency, and reliability

1. AdreView [prescribing information]. Arlington Heights, IL: GE Healthcare; 2013
2. Vik TA, Pfluger T, Kadota R, Castel V, et al. 123I-mIBG Scintigraphy in Patients With Known or Suspected Neuroblastoma: Results From a Prospective Multicenter Trial. Pediatr Blood Cancer. 2009; 52: 784-790
3. Wiseman GA, Pacak K, O’Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.